Blar i forfatter "Nakken, Sigve"

Viser treff 1-3 av 3

    • High number of kinome-mutations in non-small cell lung cancers associated with reduced immune response and poor relapse-free survival 

      Helland, Åslaug; Brustugun, Odd Terje; Nakken, Sigve; Halvorsen, Ann Rita; Dønnem, Tom; Bremnes, Roy M.; Busund, Lill-Tove; Sun, Jinchang; Lorenz, Susanne; Solberg, Steinar; Jørgensen, Lars Hilmar; Vodak, Daniel; Myklebost, Ola; Hovig, Eivind; Meza, Leonardo Zepeda (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-04-07)
      Lung cancer is the leading cause of cancer related death, and the past years’ improved insight into underlying molecular events has significantly improved outcome for specific subsets of patients. In particular, several new therapies that target protein kinases have been implemented, and many more are becoming available. We have investigated lung cancer specimens for somatic mutations in a targeted ...

    • Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study 

      Ree, Anne Hansen; Nygaard, Vigdis; Pedersen, Kjetil Boye; Heinrich, Daniel; Dueland, Svein; Bergheim, Inger Riise; Johansen, Christin; Beiske, Klaus; Negård, Anne; Lund-Iversen, Marius; Nygaard, Vegard; Hovig, Eivind; Nakken, Sigve; Nasser, Salah; Julsrud, Lars; Reisse, Claudius; Ruud, Espen Asak; Kristensen, Vessela N.; Flørenes, Vivi Ann; Geitvik, Gry; Lingjærde, Ole Christian; Børresen-Dale, Anne-Lise; Russnes, Hege Elisabeth Giercksky; Mælandsmo, Gunhild Mari; Flatmark, Kjersti (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-03-25)
      <i>Background</i>: In precision cancer medicine, the challenge is to prioritize DNA driver events, account for resistance markers, and procure sufficient information for treatment that maintains patient safety. The MetAction project, exploring how tumor molecular vulnerabilities predict therapy response, first established the required workflow for DNA sequencing and data interpretation (2014–2015). ...

    • Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma 

      Fiorito, Elisa; Szybowska, Patrycja Maria; Haugsten, Ellen Margrethe; Kostas, Michal Janusz; Øy, Geir Frode; Wiedlocha, Antoni; Singh, Sachin Kumar; Nakken, Sigve; Mælandsmo, Gunhild Mari; Fletcher, Jonathan A.; Meza, Leonardo Zepeda; Wesche, Jørgen (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-09-12)
      Background: Rhabdomyosarcoma (RMS) is a paediatric cancer driven either by fusion proteins (e.g., PAX3-FOXO1) or by mutations in key signalling molecules (e.g., RAS or FGFR4). Despite the latter providing opportunities for precision medicine approaches in RMS, there are currently no such treatments implemented in the clinic.<p> <p>Methods: We evaluated biologic properties and targeting strategies ...